Town & Country Bank & Trust CO dba First Bankers Trust CO Has $3.37 Million Stock Position in Merck & Co., Inc. $MRK

Town & Country Bank & Trust CO dba First Bankers Trust CO lessened its stake in Merck & Co., Inc. (NYSE:MRK) by 35.3% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 31,971 shares of the company’s stock after selling 17,417 shares during the quarter. Merck & Co., Inc. makes up 1.1% of Town & Country Bank & Trust CO dba First Bankers Trust CO’s holdings, making the stock its 23rd biggest position. Town & Country Bank & Trust CO dba First Bankers Trust CO’s holdings in Merck & Co., Inc. were worth $3,365,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors also recently modified their holdings of the company. DLD Asset Management LP lifted its stake in Merck & Co., Inc. by 30.1% in the 3rd quarter. DLD Asset Management LP now owns 47,500,000 shares of the company’s stock valued at $3,986,675,000 after purchasing an additional 11,000,000 shares during the last quarter. Legal & General Group Plc increased its holdings in shares of Merck & Co., Inc. by 5.9% during the 3rd quarter. Legal & General Group Plc now owns 20,659,157 shares of the company’s stock worth $1,733,923,000 after acquiring an additional 1,156,112 shares during the last quarter. Invesco Ltd. raised its stake in Merck & Co., Inc. by 16.6% in the 3rd quarter. Invesco Ltd. now owns 19,844,936 shares of the company’s stock valued at $1,665,585,000 after acquiring an additional 2,821,766 shares during the period. Ameriprise Financial Inc. raised its stake in Merck & Co., Inc. by 20.7% in the 3rd quarter. Ameriprise Financial Inc. now owns 15,933,909 shares of the company’s stock valued at $1,336,877,000 after acquiring an additional 2,735,459 shares during the period. Finally, Nordea Investment Management AB lifted its holdings in Merck & Co., Inc. by 2.0% during the 3rd quarter. Nordea Investment Management AB now owns 10,945,187 shares of the company’s stock valued at $876,600,000 after purchasing an additional 209,759 shares during the last quarter. 76.07% of the stock is currently owned by institutional investors and hedge funds.

Key Merck & Co., Inc. News

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: EU approval expands KEYTRUDA use to PD‑L1 positive, platinum‑resistant ovarian cancer — opens a new commercial indication in Europe for an established franchise, which can drive incremental revenue and utilization in a high‑unmet‑need setting. Merck Broadens Cancer And Eye Disease Pipeline As Investors Weigh Future Growth
• Positive Sentiment: Merck initiated a pivotal Phase 2b/3 trial of MK‑8748 (Tiespectus) for wet AMD — a promising ophthalmology program that, if successful, adds a non‑oncology growth vector and diversifies long‑term revenue streams. Merck Announces Initiation of Pivotal Phase 2b/3 Trial Evaluating MK-8748 (Tiespectus)
• Positive Sentiment: Positive Phase 3 CORALreef results for oral PCSK9 inhibitor (enlicitide decanoate) — if approved, an oral PCSK9 could be a major commercial opportunity in cardiovascular prevention and complement existing lipid therapies. Merck (MRK) Reports Strong Phase 3 Results for Oral PCSK9
• Positive Sentiment: Detailed Phase 2 CADENCE data for WINREVAIR released — adds evidence to a respiratory program that management can highlight to investors as part of a broader R&D pipeline story. Merck & Co. (MRK) Announces Detailed Results From the Phase 2 CADENCE Study
• Neutral Sentiment: Merck KGaA acquisition of JSR chromatography business noted in the press — this concerns Merck KGaA (a different company) and is unlikely to meaningfully affect Merck & Co.’s (MRK) near‑term fundamentals. Merck KGaA acquires JSR chromatography
• Negative Sentiment: New proposal from former President Trump to impose up to 100% tariffs on imported medicines (with carve‑outs) increases regulatory and pricing uncertainty for the sector; even with exemptions, the proposal raises near‑term headline risk and could pressure sentiment toward large pharma names like MRK until policy clarity emerges. Trump Unveils Up to 100% Tariffs on Imported Medicines With Key Exemptions
• Negative Sentiment: Sector policy debate over drug‑pricing deals continues (Lilly warns against locking pricing deals into law) — ongoing political scrutiny increases the chance of policy actions that could cap pricing or change reimbursement, a headwind for long‑term margin visibility. Lilly Pushes Back on Making Drug Price Deals Permanent

Analyst Ratings Changes

MRK has been the subject of several research analyst reports. Cantor Fitzgerald lifted their target price on shares of Merck & Co., Inc. from $116.00 to $120.00 and gave the stock a “neutral” rating in a report on Wednesday, February 4th. Zacks Research raised shares of Merck & Co., Inc. from a “strong sell” rating to a “hold” rating in a report on Tuesday, March 17th. Wells Fargo & Company raised their price objective on shares of Merck & Co., Inc. from $135.00 to $150.00 and gave the stock an “overweight” rating in a research report on Thursday, March 12th. Royal Bank Of Canada reaffirmed an “outperform” rating and issued a $142.00 target price on shares of Merck & Co., Inc. in a research report on Monday, March 30th. Finally, Morgan Stanley lifted their price target on Merck & Co., Inc. from $100.00 to $102.00 and gave the stock an “equal weight” rating in a report on Friday, December 12th. One investment analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating and seven have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $127.13.

Insider Transactions at Merck & Co., Inc.

In related news, CMO Chirfi Guindo sold 20,000 shares of the stock in a transaction that occurred on Thursday, February 5th. The shares were sold at an average price of $121.88, for a total transaction of $2,437,600.00. Following the sale, the chief marketing officer owned 80,615 shares in the company, valued at approximately $9,825,356.20. This trade represents a 19.88% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Robert M. Davis sold 47,434 shares of Merck & Co., Inc. stock in a transaction that occurred on Wednesday, February 4th. The shares were sold at an average price of $118.04, for a total transaction of $5,599,109.36. Following the completion of the transaction, the chief executive officer directly owned 443,602 shares in the company, valued at $52,362,780.08. This trade represents a 9.66% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 320,176 shares of company stock worth $38,281,735. Corporate insiders own 0.13% of the company’s stock.

Merck & Co., Inc. Price Performance

Merck & Co., Inc. stock opened at $120.62 on Friday. The firm has a market cap of $298.21 billion, a PE ratio of 16.57, a price-to-earnings-growth ratio of 2.44 and a beta of 0.26. The company has a debt-to-equity ratio of 0.89, a current ratio of 1.54 and a quick ratio of 1.30. The stock’s fifty day moving average price is $117.72 and its two-hundred day moving average price is $103.23. Merck & Co., Inc. has a one year low of $73.31 and a one year high of $125.14.

Merck & Co., Inc. (NYSE:MRK) last released its earnings results on Tuesday, February 3rd. The company reported $2.04 earnings per share for the quarter, beating analysts’ consensus estimates of $2.01 by $0.03. Merck & Co., Inc. had a return on equity of 44.57% and a net margin of 28.08%.The firm had revenue of $16.40 billion during the quarter, compared to the consensus estimate of $16.19 billion. During the same period in the prior year, the company posted $1.72 EPS. The company’s revenue was up 5.0% compared to the same quarter last year. Merck & Co., Inc. has set its FY 2026 guidance at 5.000-5.150 EPS. As a group, research analysts expect that Merck & Co., Inc. will post 9.01 EPS for the current fiscal year.

Merck & Co., Inc. Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, April 7th. Shareholders of record on Monday, March 16th will be paid a dividend of $0.85 per share. This represents a $3.40 dividend on an annualized basis and a yield of 2.8%. The ex-dividend date is Monday, March 16th. Merck & Co., Inc.’s dividend payout ratio is presently 46.70%.

Merck & Co., Inc. Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.